The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1b study evaluating IL-1β and PD-1 targeting with chemotherapy in metastatic pancreatic cancer (PanCAN-SR1).
 
Paul Eliezer Oberstein
Consulting or Advisory Role - AstraZeneca; BTG; Ipsen; Merck; QED Therapeutics; Rubius Therapeutics; TYME
Speakers' Bureau - AstraZeneca
Research Funding - Arcus Biosciences (Inst); Merck (Inst); Rafael Pharmaceuticals (Inst); Roche/Genentech (Inst)
Expert Testimony - Ipsen
Travel, Accommodations, Expenses - Merck
 
Osama E. Rahma
Employment - Outcomes4me
Leadership - Outcomes4me
Honoraria - Alaunus Global; Clinical Care Options; Leerink; Merck; MI Bioresearch; PRMA Consulting
Consulting or Advisory Role - Alcimed; Bayer; Celgene; Defined Health; Five Prime Therapeutics; Genentech; Gfk; GlaxoSmithKline; Imvax; Leerink; Leerink; Maverick Therapeutics; Merck; PureTech; Putnam Associates; Sobi
Research Funding - Amgen (Inst); Merck
Patents, Royalties, Other Intellectual Property - PD-1/PD-L1 (Inst); Pending patent (DFCI 2386.010) (Inst)
Travel, Accommodations, Expenses - Clinical Care Options; Genentech; Merck; PRMA Consulting; PureTech
 
Nina Beri
No Relationships to Disclose
 
Amy C. Stoll-D'Astice
Stock and Other Ownership Interests - Abbott Laboratories; Bristol-Myers Squibb/Celgene (I); Cerner (I); Cigna (I); Gilead Sciences (I); Lilly (I); Moderna Therapeutics; Regeneron
 
Anne-Marie Duliege
Employment - Rigel
Leadership - Rigel
Stock and Other Ownership Interests - Rigel
Consulting or Advisory Role - Federation Bio
 
Saloney Nazeer
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Matthew Squires
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Dafna Bar-Sagi
Patents, Royalties, Other Intellectual Property - The license with Inthera was amended to remove the NYU patents from the license, so no royalties or other payments are expected going forward. NYU holds equity in Inthera valued at approximately $16,000. If this equity gets liquidated, Dr. Bar-Sagi will r; The license with Inthera was amended to remove the NYU patents from the license, so no royalties or other payments are expected going forward. NYU holds equity in Inthera valued at approximately $16,000. If this equity gets liquidated, Dr. Bar-Sagi will r
 
Brian M. Wolpin
Honoraria - Celgene; G1 Therapeutics
Consulting or Advisory Role - BioLineRx; Celgene; G1 Therapeutics; Genentech; GRAIL; GRAIL
Research Funding - Celgene; Lilly
 
Stephanie Dougan
Leadership - Kojin Therapeutics; Neoleukin Therapeutics (I)
Stock and Other Ownership Interests - Kojin Therapeutics
Consulting or Advisory Role - GlaxoSmithKline
Research Funding - Bristol-Myers Squibb; Lilly; Novartis Institutes for BioMedical Research
Patents, Royalties, Other Intellectual Property - Patent pending for an HSV immunotherapeutic delivery vector
 
Diane M. Simeone
Consulting or Advisory Role - Celgene
Research Funding - Abbvie
Patents, Royalties, Other Intellectual Property - small royalties for my patent on pancreatic cancer stem cells also I receive an annual royalty for a textbook I edited Greenfields Textbook of Surgery
Travel, Accommodations, Expenses - Konica Minolta Precision Medicine